Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Aviles-Izquierdo, JA; Nieto-Benito, LM; Lazaro-Ochaita, P; Escat-Cortes, JL; Marquez-Rodas, I; Mercader-Cidoncha, E.

Prognostic significance of sentinel node biopsy status in cutaneous melanoma: a 21-years prospective study from a single institution

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(9): 1611-1618 [doi:10.1007/s12094-020-02306-w]

Friedlaender, A; Metro, G; Signorelli, D; Gili, A; Economopoulou, P; Roila, F; Banna, G; De Toma, A; Camerini, A; Christopoulou, A; Lo Russo, G; Banini, M; Galetta, D; Jimenez, B; Collazo-Lorduy, A; Calles, A; Baxevanos, P; Linardou, H; Kosmidis, P; Mountzios, G; Garassino, MC; Addeo, A.

Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score >= 50% treated with front-line pembrolizumab

Acta Oncologica. 2020; 59(9): 1058-1063 Nº de citas: 34 [doi:10.1080/0284186X.2020.1781249]

Van Cutsem, E; Danielewicz, I; Saunders, MP; Pfeiffer, P; Argiles, G; Borg, C; Glynne-Jones, R; Punt, CJA; Van de Wouw, AJ; Fedyanin, M; Stroyakovskiy, D; Kroening, H; Garcia-Alfonso, P; Wasan, H; Falcone, A; Kanehisa, A; Egorov, A; Aubel, P; Amellal, N; Moiseenko, V.

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

ANNALS OF ONCOLOGY. 2020; 31(9): 1160-1168 Nº de citas: 47 [doi:10.1016/j.annonc.2020.05.024]

Goetz, MP; Martin, M; Tokunaga, E; Park, IH; Huober, J; Toi, M; Stoffregen, C; Shekarriz, S; Andre, V; Gainford, MC; Price, GL; Johnston, S.

Health-RelatedQuality of Life inMONARCH3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy inHR+,HER2-Advanced Breast Cancer

ONCOLOGIST. 2020; 25(9): 1346-1354 Nº de citas: 43 [doi:10.1634/theoncologist.2020-0084]

Escudero-Vilaplana, V; Collado-Borrell, R; Hoyo-Munoz, A; Gimenez-Manzorro, A; Calles, A; Osorio, S; Herranz-Alonso, A; Sanjurjo-Saez, M.

Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice

EXPERT OPINION ON DRUG SAFETY. 2020; 19(8): 1041-1048 Nº de citas: 9 [doi:10.1080/14740338.2020.1781089]

Vera, R; Gomez, ML; Ayuso, JR; Figueras, J; Garcia-Alfonso, P; Martinez, V; Lacasta, A; Ruiz-Casado, A; Safont, MJ; Aparicio, J; Campos, JM; Camara, JC; Martin-Richard, M; Montagut, C; Pericay, C; Vieitez, JM; Falco, E; Jorge, M; Marin, M; Salgado, M; Viudez, A.

Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study

Cancers. 2020; 12(8): Nº de citas: 9 [doi:10.3390/cancers12082259]

Izquierdo, JAA; Lopez, IM; Morillo, PS; Rodas, IM; Cidoncha, EM.

Utility of PET/CT in patients with stage I-III melanoma

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(8): 1414-1417 Nº de citas: 8 [doi:10.1007/s12094-019-02252-2]

Camps Herrero, C; Batista, N; Diaz Fernandez, N; Escobar Alvarez, Y; Gonzalo Gomez, A; Isla Casado, D; Salud, A; Terrasa Pons, J; Guillem Porta, V.

Breakthrough cancer pain: review and calls to action to improve its management

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(8): 1216-1226 Nº de citas: 26 [doi:10.1007/s12094-019-02268-8]

Carmona-Bayonas, A; Gomez, D; de Castro, EM; Segura, PP; Langa, JM; Jimenez-Fonseca, P; Canovas, MS; Moran, LO; Escobar, IG; Blanco, ABR; Perez, IF; de Prado, PM; Balanya, RPI; Verduguez, TQ; Rodriguez-Lescure, A; Munoz, A.

A snapshot of cancer-associated thromboembolic disease in 2018-2019: First data from the TESEO prospective registry

EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2020; 78: 41-49 Nº de citas: 29 [doi:10.1016/j.ejim.2020.05.031]

Galeano-Valle, F; Perez-Rus, G; Demelo-Rodriguez, P; Ordieres-Ortega, L; Ortega-Moran, L; Munoz-Martin, AJ; Medina-Molina, S; Alvarez-Sala-Walther, LA; del-Toro-Cervera, J.

Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(8): 1312-1320 Nº de citas: 2 [doi:10.1007/s12094-019-02258-w]

Sanchis, AC; Gallego, J; Hernandez, R; Arrazubi, V; Custodio, A; Cano, JM; Aguado, G; Macias, I; Lopez, C; Lopez, F; Visa, L; Garrido, M; Lago, NM; Montes, AF; Limon, ML; Azkarate, A; Pimentel, P; Reguera, P; Ramchandani, A; Cacho, JD; Carnicero, AM; Granja, M; Richard, MM; Perez, CH; Hurtado, A; Serra, O; Buxo, E; Tocino, RV; Jimenez-Fonseca, P; Carmona-Bayonas, A.

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

PLoS One. 2020; 15(7): Nº de citas: 17 [doi:10.1371/journal.pone.0235848]

Amor-Garcia, MA; Collado-Borrell, R; Escudero-Vilaplana, V; Melgarejo-Ortuno, A; Herranz-Alonso, A; Arija, JAA; Sanjurjo-Saez, M.

Assessing Apps for Patients with Genitourinary Tumors Using the Mobile Application Rating Scale (MARS): Systematic Search in App Stores and Content Analysis

JMIR mHealth and uHealth. 2020; 8(7): Nº de citas: 36 [doi:10.2196/17609]

Wainberg, ZA; Feeney, K; Lee, MA; Munoz, A; Gracian, AC; Lonardi, S; Ryoo, BY; Hung, AN; Lin, Y; Bendell, J; Hecht, JR.

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

BMC CANCER. 2020; 20(1): Nº de citas: 23 [doi:10.1186/s12885-020-07110-x]

Onesti, CE; Rugo, HS; Generali, D; Peeters, M; Zaman, K; Wildiers, H; Harbeck, N; Martin, M; Cristofanilli, M; Cortes, J; Tjan-Heijnen, V; Hurvitz, SA; Berchem, G; Tagliamento, M; Campone, M; Bartsch, R; De Placido, S; Puglisi, F; Rottey, S; Muller, V; Ruhstaller, T; Machiels, JP; Conte, P; Awada, A; Jerusalem, G.

Oncological care organisation during COVID-19 outbreak

Esmo Open. 2020; 5(4): Nº de citas: 28 [doi:10.1136/esmoopen-2020-000853]

Segui, MA; Cruz, JJ; Alba, E; Feliu, J; Jara, C; Rivera, F; Lescure, AR; Lorenzo, A; Martin, M.

Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain

CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(7): 1049-1058 [doi:10.1007/s12094-019-02230-8]

Trilla-Fuertes, L; Ghanem, I; Maurel, J; G-Pastrian, L; Mendiola, M; Pena, C; Lopez-Vacas, R; Prado-Vazquez, G; Lopez-Camacho, E; Zapater-Moros, A; Heredia, V; Cuatrecasas, M; Garcia-Alfonso, P; Capdevila, J; Conill, C; Garcia-Carbonero, R; Heath, KE; Ramos-Ruiz, R; Llorens, C; Campos-Barros, A; Gamez-Pozo, A; Feliu, J; Vara, JAF.

Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma

Translational Oncology. 2020; 13(7): Nº de citas: 9 [doi:10.1016/j.tranon.2020.100778]

Paz-Ares, L; Kim, TM; Vicente, D; Felip, E; Lee, DH; Lee, KH; Lin, CC; Flor, MJ; Di Nicola, M; Alvarez, RM; Dussault, I; Helwig, C; Ojalvo, LS; Gulley, JL; Cho, BC.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

JOURNAL OF THORACIC ONCOLOGY. 2020; 15(7): 1210-1222 Nº de citas: 160 [doi:10.1016/j.jtho.2020.03.003]

Garcia-Gonzalez, X; Kaczmarczyk, B; Abarca-Zabalia, J; Thomas, F; Garcia-Alfonso, P; Robles, L; Pachon, V; Vaz, A; Salvador-Martin, S; Sanjurjo-Saez, M; Lopez-Fernandez, LA.

New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2020; 86(1): 45-54 Nº de citas: 13 [doi:10.1007/s00280-020-04093-1]